Orthofix Readies For Bone Protein Product; Cites Hurdles For Acceptance
This article was originally published in The Gray Sheet
Executive Summary
Orthofix is exploring the possibility of conducting clinical trials with its electrical stimulation products and Medtronic's InFuse BMP-2 to demonstrate a benefit for bone morphogenetic protein when used in conjunction with e-stim
You may also be interested in...
Orthofix’ $150 Mil. Breg Purchase Will Produce PoC “Gatekeeper” – CEO
Orthofix will gain access to Breg Inc.'s sales and distribution relationships with general orthopedic offices as part of a $150 mil. acquisition to expand into spinal, reconstruction and trauma orthopedic franchises
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.